Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Mcl-1 gene essential for survival of antibody-producing cells

Scientists have identified the gene essential for survival of antibody-producing cells, a finding that could lead to better treatments for diseases where these cells are out of control, such as myeloma and chronic immune disorders.

3 Feb 2013

OncoEthix initiates OTX015 Phase I study in hematologic malignancies

OncoEthix, the Swiss-based specialist in oncology drug development, announces progress in its Phase I study of OTX015, a novel BET bromodomain inhibitor, with the first dosing of a patient.

31 Jan 2013

OncoPep commences PVX-410 Phase 1/2a trial in smoldering multiple myeloma

OncoPep, Inc. today announced that the Company has initiated a Phase 1/2a clinical trial evaluating PVX-410, a multi-peptide therapeutic cancer vaccine, in patients with smoldering multiple myeloma, an asymptomatic precursor of multiple myeloma, which is an incurable cancer of the plasma cells.

30 Jan 2013

New study may help treat patients with multiple myeloma

A study led by Robert G. Hawley, Ph.D., professor and chair of the department of anatomy and regenerative biology at the George Washington University (GW) School of Medicine and Health Sciences (SMHS), may help predict which patients with multiple myeloma will respond better to certain treatments.

25 Jan 2013

Positive results from BioInvent's BI-505 phase I study on multiple myeloma

BioInvent International announced today the first results from the BI-505 phase I study in patients with multiple myeloma.

24 Jan 2013

Pomalidomide safe, effective and extends overall survival for patients with multiple myeloma

Researchers at Moffitt Cancer Center and colleagues have investigated the safety, efficacy and the maximum tolerated dose of pomalidomide for patients with multiple myeloma who have disease relapsed after treatments with other drugs, such as bortezomib and lenalidomide.

24 Jan 2013

Study may help predict which multiple myeloma patients will respond better to certain treatments

24 Jan 2013

Scientists discover role of OTUD7B enzyme as TRAF3's protector

Marked for death with molecular tags that act like a homing signal for a cell's protein-destroying machinery, a pivotal enzyme is rescued by another molecule that sweeps the telltale targets off in the nick of time.

21 Jan 2013

Over-expression of NEK2 in cancer cells significantly enhances drug resistance

Increased NEK2 gene expression linked to increased drug resistance, faster cancer growth, and poorer patient outcome - The finding may improved diagnostic and prognostic tools for cancer care and could lead to improved cancer therapies

16 Jan 2013

Farmers face increased risk for multiple myeloma

People working as farmers and those with long-term exposure to pesticides have an increased risk for multiple myeloma, results of a large European study suggest.

2 Jan 2013

World Trade Center rescue workers may face increased cancer risk

People who were involved in the rescue and recovery operation at the World Trade Center are at an increased risk for certain types of cancer, including prostate, thyroid, and myeloma, study findings suggest.

31 Dec 2012

Study finds increased risk of cancers among rescue/recovery workers after WTC terrorist attack

Among rescue and recovery workers exposed to the dust, debris, and fumes following the World Trade Center terrorist attack, there was an increased incidence of prostate and thyroid cancers and multiple myeloma, although it is not clear how big a factor medical screening and non-WTC risk factors contributed to these increases, according to a study in the December 19 issue of JAMA.

21 Dec 2012

Study finds no clear indication 9/11 debris causes cancer

The study, published in the Journal of the American Medical Association, examined the health of nearly 56,000 people.

20 Dec 2012

Multiple Myeloma Research Foundation, Bristol-Myers Squibb announce partnership

The Multiple Myeloma Research Foundation (MMRF) today announced that Bristol-Myers Squibb has joined the MMRF pre-competitive consortium (PCC) to discover and accelerate new approaches to treating multiple myeloma through the organization's Personalized Medicine Initiative (PMI).

15 Dec 2012

Scientists discover FAIM molecule as potential biomarker for bone marrow cancer

Singapore scientists have identified FAIM, a molecule that typically prevents cell death, as a potential biomarker to identify an incurable form of cancer in the bone marrow.

14 Dec 2012

Pfizer, Ligand announce FDA acceptance of bazedoxifene/conjugated estrogens NDA

Pfizer Inc. and Ligand Pharmaceuticals Incorporated today announced that the United States Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized women for the treatment of moderate-to-severe vasomotor symptoms (VMS) and vulvar and vaginal atrophy (VVA) associated with menopause, as well as the prevention of postmenopausal osteoporosis.

14 Dec 2012

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Aeterna Zentaris Inc. today announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas.

12 Dec 2012

Pomalidomide safe and effective in treating multiple myeloma

A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting is taking place December 8-11, 2012 in Atlanta.

11 Dec 2012

Ligand commences PG-free melphalan pivotal trial in multiple myeloma

Ligand Pharmaceuticals Incorporated announced today that it has initiated a pivotal trial of Captisol-enabled, propylene glycol-free (PG-free) high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma.

11 Dec 2012

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase (HDAC) 1/2 inhibitor for the treatment of sickle cell disease (SCD) and beta-thalassemia (bT) at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia.

11 Dec 2012